The Glutamatergic Dysfunction Hypothesis for Schizop

Harvard Review of Psychiatry 3, 241-253 DOI: 10.3109/10673229609017192

Citation Report

#	Article	IF	CITATIONS
1	D-cycloserine added to clozapine for patients with schizophrenia. American Journal of Psychiatry, 1996, 153, 1628-1630.	7.2	180
2	Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex. Journal of Neuroscience, 1997, 17, 2921-2927.	3.6	1,607
3	Olanzapine: A New Antipsychotic Agent with Efficacy in the Management of Schizophrenia. Annals of Pharmacotherapy, 1997, 31, 1325-1334.	1.9	32
4	Glutamate in schizophrenia: clinical and research implications. Schizophrenia Research, 1997, 27, 157-168.	2.0	91
5	The Glutamate Hypothesis of Schizophrenia. CNS Drugs, 1997, 7, 47-67.	5.9	22
6	Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. Journal of Neural Transmission, 1997, 104, 761-766.	2.8	78
7	The effects of early and sustained intervention on the long-term morbidity of schizophrenia. Journal of Psychiatric Research, 1998, 32, 169-177.	3.1	69
8	Effects of antipsychotics, vitamin E, and MK-801 on dopamine dynamics in the rat brain following discontinuation of cocaine. Psychiatry Research, 1998, 80, 213-225.	3.3	1
9	Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants. Behavioural Brain Research, 1998, 97, 59-68.	2.2	19
10	Gene expression studies of mRNAs encoding the NMDA receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis- and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug treatment. Molecular Brain Research, 1998, 54, 92-100.	2.3	23
11	D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 1998, 44, 1081-1089.	1.3	586
12	Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats. , 1998, 281, 1349-1352.		923
13	Analysis of a Gene Encoding Two Glycine Transporter Variants Reveals Alternative Promoter Usage and a Novel Gene Structure. Journal of Biological Chemistry, 1998, 273, 29077-29085.	3.4	58
14	A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15718-15723.	7.1	714
15	Negative Symptoms in Schizophrenia: Neurobiological Models and Treatment Response. Harvard Review of Psychiatry, 1998, 6, 59-77.	2.1	57
16	Synaptic Basis of Cortical Persistent Activity: the Importance of NMDA Receptors to Working Memory. Journal of Neuroscience, 1999, 19, 9587-9603.	3.6	836
17	Neuroscience and Psychopharmacology into the Next Millennium. CNS Spectrums, 1999, 4, 36-52.	1.2	0
18	Panmodal Processing Imprecision as a Basis for Dysfunction of Transient Memory Storage Systems in Schizophrenia. Schizophrenia Bulletin, 1999, 25, 763-775.	4.3	89

#	Article	IF	CITATIONS
19	Clozapine for Comorbid Substance Use Disorder and Schizophrenia: Do Patients with Schizophrenia Have a Reward-Deficiency Syndrome That Can Be Ameliorated by Clozapine?. Harvard Review of Psychiatry, 1999, 6, 287-296.	2.1	149
20	NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders. Harvard Review of Psychiatry, 1999, 7, 125-143.	2.1	210
21	Excitatory amino acid transporters as emerging targets for central nervous system therapeutics. Expert Opinion on Therapeutic Targets, 1999, 3, 543-570.	1.0	14
22	Cortically driven Fos induction in the striatum is amplified by local dopamine D2-class receptor blockade. European Journal of Neuroscience, 1999, 11, 4309-4319.	2.6	27
23	Forced Normalization: Clinical and Therapeutic Relevance. Epilepsia, 1999, 40, s57-s64.	5.1	101
24	Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Molecular Psychiatry, 1999, 4, 418-428.	7.9	83
25	Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. Journal of Psychiatric Research, 1999, 33, 513-521.	3.1	236
26	Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Research, 1999, 843, 171-183.	2.2	101
27	Competitive NMDA receptor antagonists disrupt prepulse inhibition without reduction of startle amplitude in a dopamine receptor-independent manner in mice. European Journal of Pharmacology, 1999, 364, 133-140.	3.5	22
28	Electrophysiological effects of E-5842, a σ1 receptor ligand and potential atypical antipsychotic, on A9 and A10 dopamine neurons. European Journal of Pharmacology, 1999, 378, 31-37.	3.5	18
29	The concept of target features in schizophrenia research. Acta Psychiatrica Scandinavica, 1999, 99, 2-11.	4.5	84
30	Proton Magnetic Resonance Spectroscopy in the Frontal and Temporal Lobes of Neuroleptic Naive Patients with Schizophrenia. Neuropsychopharmacology, 1999, 20, 131-140.	5.4	93
31	Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists. Neuropsychopharmacology, 1999, 21, S143-S157.	5.4	59
32	Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. , 1999, 56, 72-75.		54
33	MK-801-induced expression of Fos protein family members in the rat retrosplenial granular cortex. Journal of Neuroscience Research, 1999, 57, 719-729.	2.9	7
34	Cognitive dysfunction in schizophrenia: unifying basic research and clinical aspects. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S69-S82.	3.2	85
35	An integrated view of pathophysiological models of schizophrenia. Brain Research Reviews, 1999, 29, 250-264.	9.0	156
36	Do hallucinogens cause residual neuropsychological toxicity?. Drug and Alcohol Dependence, 1999, 53, 247-256.	3.2	71

#	Article	IF	CITATIONS
37	D2 dopamine receptor but not AMPA and kainate glutamate receptor genes show altered expression in response to long term treatment with trans- and cis-flupenthixol in the rat brain. Molecular Brain Research, 1999, 68, 14-21.	2.3	4
38	Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia. Cell, 1999, 98, 427-436.	28.9	1,002
39	Symptom provocation studies in psychiatric disorders: scientific value, risks, and future. Biological Psychiatry, 1999, 46, 1060-1080.	1.3	27
40	Comparative pharmacology of bipolar disorder and schizophrenia. Schizophrenia Research, 1999, 39, 153-158.	2.0	36
41	A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia. Archives of General Psychiatry, 1999, 56, 21.	12.3	410
42	Age Disorientation in Schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 350-358.	1.8	16
43	Deficits in Auditory and Visual Context-Dependent Processing in Schizophrenia. Archives of General Psychiatry, 2000, 57, 1131.	12.3	210
44	Presence of NMDA-type glutamate receptors in cingulate corticostriatal terminals and their postsynaptic targets. , 2000, 35, 300-310.		28
45	Neurobiology of schizophrenia. Annals of Neurology, 2000, 48, 556-566.	5.3	106
46	Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex. European Journal of Neuroscience, 2000, 12, 1420-1430.	2.6	65
47	Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory. British Journal of Pharmacology, 2000, 130, 33-40.	5.4	34
48	Effects of Ketamine, MK-801, and Amphetamine on Regional Brain 2-Deoxyglucose Uptake in Freely Moving Mice. Neuropsychopharmacology, 2000, 22, 400-412.	5.4	89
49	Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine. European Journal of Pharmacology, 2000, 398, 1-10.	3.5	28
50	Glutamate Receptor Ion Channels: Activators and Inhibitors. Handbook of Experimental Pharmacology, 2000, , 415-478.	1.8	15
51	Intracortical Mechanisms of Mismatch Negativity Dysfunction in Schizophrenia. Audiology and Neuro-Otology, 2000, 5, 207-215.	1.3	159
52	Fluoxetine prevents PCP- and MK801-induced HSP70 expression in injured limbic cortical neurons of rats. Biological Psychiatry, 2000, 47, 836-841.	1.3	15
53	Inhibition of striatal dopamine release by glycine and glycyldodecylamide. Brain Research Bulletin, 2000, 52, 213-216.	3.0	26
54	The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Research Reviews, 2000, 31, 371-384.	9.0	300

	Сітат	ION REPORT	
#	Article	IF	CITATIONS
55	Differential effects of MK-801 on cerebrocortical neuronal injury in C57BL/6J, NSA, and ICR Mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2000, 24, 925-938.	4.8	5
56	Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Research - Neuroimaging, 2000, 98, 163-175.	1.8	80
57	Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment. Life Sciences, 2000, 66, 1071-1078.	4.3	15
58	A review of MRI findings in schizophrenia. Schizophrenia Research, 2001, 49, 1-52.	2.0	2,143
59	Pathophysiology of Schizophrenia. , 2001, , 231-252.		0
60	Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biological Psychiatry, 2001, 50, 750-757.	1.3	105
61	Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biological Psychiatry, 2001, 50, 729-742.	1.3	183
62	Psychopathology and the binding problem. Medical Hypotheses, 2001, 57, 718-723.	1.5	4
63	Could platelet activating factor play a role in developmental dyslexia?. Prostaglandins Leukotrienes and Essential Fatty Acids, 2001, 64, 173-180.	2.2	8
64	Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2001, 25, 691-707.	4.8	86
65	Semantic disturbance in schizophrenia and its relationship to the cognitive neuroscience of attention. Biological Psychology, 2001, 57, 23-46.	2.2	34
66	Genetic animal models: focus on schizophrenia. Trends in Neurosciences, 2001, 24, 527-533.	8.6	197
67	A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications. Clinical Neuropharmacology, 2001, 24, 43-49.	0.7	135
68	Topiramate Improves Deficit Symptoms in a Patient with Schizophrenia when Added to a Stable Regimen of Antipsychotic Medication. Clinical Neuropharmacology, 2001, 24, 290-294.	0.7	31
69	Amygdalar activation alters the hippocampal GABA system: ?Partial? modelling for postmortem changes in schizophrenia. Journal of Comparative Neurology, 2001, 431, 129-138.	1.6	90
70	NMDA receptor regulation of memory and behavior in humans. Hippocampus, 2001, 11, 529-542.	1.9	221
71	Blunted brain metabolic response to ketamine in mice lacking D1A dopamine receptors. Brain Research, 2001, 894, 167-180.	2.2	41
72	Differential and Region-Specific Activation of Mitogen-Activated Protein Kinases Following Chronic Administration of Phencyclidine in Rat Brain. Neuropsychopharmacology, 2001, 24, 267-277.	5.4	32

#	Article	IF	CITATIONS
73	Expression of AMPA Receptor Flip and Flop mRNAs in the Nucleus Accumbens and Prefrontal Cortex after Neonatal Ventral Hippocampal Lesions. Neuropsychopharmacology, 2001, 24, 253-266.	5.4	22
74	Effects of Age and Gender on the Expression of Brain-Derived Neurotrophic Factor mRNA in Rat Retrosplenial Cortex Following Administration of Dizocilpine. Neuropsychopharmacology, 2001, 25, 258-266.	5.4	29
75	Inhibition of vesicular glutamate storage and exocytotic release by Rose Bengal. Journal of Neurochemistry, 2001, 77, 34-42.	3.9	57
76	Progressive Brain Volume Changes and the Clinical Course of Schizophrenia in Men. Archives of General Psychiatry, 2001, 58, 148.	12.3	389
77	Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proceedings of the United States of America, 2001, 98, 11047-11054.	7.1	153
78	Adjunctive high-dose glycine in the treatment of schizophrenia. International Journal of Neuropsychopharmacology, 2001, 4, 385-91.	2.1	170
79	Genes, environment and schizophrenia. British Journal of Psychiatry, 2001, 178, s18-s24.	2.8	230
80	Recent advances in the pharmacotherapy of autism. Expert Review of Neurotherapeutics, 2002, 2, 499-510.	2.8	11
81	Association between the ionotropic glutamate receptor kainate 3 (GRIK3) ser310ala polymorphism and schizophrenia. Molecular Psychiatry, 2002, 7, 416-418.	7.9	69
82	Effects of cocaine and reserpine administration on RNA editing of rat 5-HT2C receptor estimated by primer extension combined with denaturing high-performance liquid chromatography. Pharmacogenomics Journal, 2002, 2, 335-340.	2.0	14
83	Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1661-1664.	7.1	154
84	Review of Antipsychotic Medication Administration: A Proposal of Intermittent Dosing. Schizophrenia Bulletin, 2002, 28, 203-222.	4.3	20
85	d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Research, 2002, 56, 19-23.	2.0	109
86	Glutamatergic Mechanisms in Schizophrenia. Annual Review of Pharmacology and Toxicology, 2002, 42, 165-179.	9.4	569
87	Neuroanatomy and neurophysiology in schizophrenia. Neuroscience Research, 2002, 43, 93-110.	1.9	69
88	Adaptation to chronic PCP results in hyperfunctional NMDA and hypofunctional GABAA synaptic receptors. Neuroscience, 2002, 113, 1-10.	2.3	35
89	Cellular perspectives on the glutamate–monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. Progress in Neurobiology, 2002, 67, 173-202.	5.7	102
90	The difference in Mismatch negativity between the acute and post-acute phase of schizophrenia. Biological Psychology, 2002, 59, 105-119.	2.2	59

#	Article	IF	CITATIONS
91	Topiramate antagonizes MK-801 in an animal model of schizophrenia. European Journal of Pharmacology, 2002, 449, 121-125.	3.5	45
92	Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Research, 2002, 951, 166-176.	2.2	51
93	Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Research, 2002, 954, 11-20.	2.2	122
94	Neuropharmacological Profile of a Novel Potential Atypical Antipsychotic Drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate). Neuropsychopharmacology, 2002, 26, 456-467.	5.4	29
95	Human metabotropic glutamate receptor 2 gene (GRM2): Chromosomal sublocalization (3p21.1-p21.2) and genomic organization. American Journal of Medical Genetics Part A, 2002, 114, 12-14.	2.4	9
96	Metabotropic glutamate receptor 3 (<i>GRM3</i>) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. American Journal of Medical Genetics Part A, 2002, 114, 46-50.	2.4	87
97	Neuroprotective effects of estradiol-17β: implications for psychiatric disorders. Archives of Women's Mental Health, 2002, 5, 105-110.	2.6	19
98	Glutamate Receptor Genes. Molecular Neurobiology, 2002, 25, 191-212.	4.0	43
99	Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia. Annals of the New York Academy of Sciences, 2003, 1003, 318-327.	3.8	402
100	Glutamatergic Animal Models of Schizophrenia. Annals of the New York Academy of Sciences, 2003, 1003, 131-137.	3.8	131
101	Behavioral analysis of the consequences of chronic blockade of NMDA-type glutamate receptors in the early postnatal period in rats. Neuroscience and Behavioral Physiology, 2003, 33, 123-131.	0.4	8
102	NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology, 2003, 169, 215-233.	3.1	477
103	Effects of estrogen on brain development and neuroprotection—implications for negative symptoms in schizophrenia11Part of this review was presented at the Seventh International Congress of Biological Psychiatry in Berlin, Germany, 1–7 July 2001 Psychoneuroendocrinology, 2003, 28, 83-96.	2.7	246
104	Interaction of stress and strain on glutamatergic neurotransmission: relevance to schizophrenia. Pharmacology Biochemistry and Behavior, 2003, 74, 351-356.	2.9	21
105	The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacology Biochemistry and Behavior, 2003, 74, 811-825.	2.9	99
106	Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. , 2003, 97, 153-179.		291
107	Time-dependent changes in gene expression profiles of midbrain dopamine neurons following haloperidol administration. Journal of Neurochemistry, 2003, 87, 205-219.	3.9	30
108	Conventional and Atypical Antipsychotics in the Elderly. Clinical Drug Investigation, 2003, 23, 287-322.	2.2	40

#	Article	IF	CITATIONS
109	Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent. Life Sciences, 2003, 73, 2355-2361.	4.3	18
110	Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal–lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biological Psychiatry, 2003, 54, 1162-1170.	1.3	108
111	Chronic neonatal N-methyl-d-aspartate receptor blockade induces learning deficits and transient hypoactivity in young rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 787-794.	4.8	47
112	Decreased Serum Levels of D-Serine in Patients With Schizophrenia. Archives of General Psychiatry, 2003, 60, 572.	12.3	461
113	Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia. Behavioral and Brain Sciences, 2003, 26, 65-82.	0.7	445
114	Progressive Decrease of Left Heschl Gyrus and Planum Temporale Gray Matter Volume in First-Episode Schizophrenia. Archives of General Psychiatry, 2003, 60, 766.	12.3	337
115	Increased Expression of c-Jun Transcription Factor in Cerebellar Vermis of Patients with Schizophrenia. Neuropsychopharmacology, 2003, 28, 1506-1514.	5.4	15
116	Chronic Administration of Haloperidol and Olanzapine Attenuates Ketamine-Induced Brain Metabolic Activation. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 999-1005.	2.5	29
117	Dehydroepiandrosterone Augmentation in the Management of Negative, Depressive, and Anxiety Symptoms in Schizophrenia. Archives of General Psychiatry, 2003, 60, 133.	12.3	200
118	Regulation of Glutamate Carboxypeptidase II Function in Corticolimbic Regions of Rat Brain by Phencyclidine, Haloperidol, and Clozapine. Neuropsychopharmacology, 2003, 28, 1227-1234.	5.4	25
119	Progressive Decrease of Left Superior Temporal Gyrus Gray Matter Volume in Patients With First-Episode Schizophrenia. American Journal of Psychiatry, 2003, 160, 156-164.	7.2	370
120	Adjuvant Topiramate Administration: A Pharmacologic Strategy for Addressing NMDA Receptor Hypofunction in Schizophrenia. Clinical Neuropharmacology, 2003, 26, 199-206.	0.7	33
121	Signaling molecules and receptor transduction cascades that regulate nmda receptor-mediated synaptic transmission. International Review of Neurobiology, 2003, 54, 51-106.	2.0	42
122	Spatial integration in perception and cognition: An empirical approach to the pathophysiology of schizophrenia. Behavioral and Brain Sciences, 2003, 26, 86-87.	0.7	0
123	A wide-spectrum coordination model of schizophrenia. Behavioral and Brain Sciences, 2003, 26, 84-85.	0.7	0
124	NMDA synapses can bias competition between object representations and mediate attentional selection. Behavioral and Brain Sciences, 2003, 26, 100-101.	0.7	3
125	No blind schizophrenics: Are NMDA-receptor dynamics involved?. Behavioral and Brain Sciences, 2003, 26, 103-104.	0.7	12
126	Reconciling schizophrenic deficits in top-down and bottom-up processes: Not yet. Behavioral and Brain Sciences, 2003, 26, 96-96.	0.7	1

#	Article	IF	CITATIONS
127	Cognitive coordination and its neurobiological bases: A new continent to explore. Behavioral and Brain Sciences, 2003, 26, 110-137.	0.7	6
128	The ketamine model for schizophrenia. Behavioral and Brain Sciences, 2003, 26, 82-83.	0.7	82
129	Is sensory gating a form of cognitive coordination?. Behavioral and Brain Sciences, 2003, 26, 94-95.	0.7	0
130	Context, connection, and coordination: The need to switch. Behavioral and Brain Sciences, 2003, 26, 97-97.	0.7	0
131	Inferring contextual field interactions from scalp EEG. Behavioral and Brain Sciences, 2003, 26, 99-100.	0.7	0
132	Mechanisms of disrupted language comprehension in schizophrenia. Behavioral and Brain Sciences, 2003, 26, 87-88.	0.7	5
133	Linking brain to mind in normal behavior and schizophrenia. Behavioral and Brain Sciences, 2003, 26, 90-90.	0.7	1
134	Combating fuzziness with computational modeling. Behavioral and Brain Sciences, 2003, 26, 107-108.	0.7	0
135	Cortical connectivity in high-frequency beta-rhythm in schizophrenics with positive and negative symptoms. Behavioral and Brain Sciences, 2003, 26, 105-106.	0.7	1
136	High-frequency synchronisation in schizophrenia: Too much or too little?. Behavioral and Brain Sciences, 2003, 26, 109-110.	0.7	4
137	Theory of mind in schizophrenia: Damaged module or deficit in cognitive coordination?. Behavioral and Brain Sciences, 2003, 26, 95-96.	0.7	7
138	Context rules. Behavioral and Brain Sciences, 2003, 26, 85-85.	0.7	6
139	Setting domain boundaries for convergence of biological and psychological perspectives on cognitive coordination in schizophrenia. Behavioral and Brain Sciences, 2003, 26, 88-89.	0.7	6
140	Where the rubber meets the road: The importance of implementation. Behavioral and Brain Sciences, 2003, 26, 83-84.	0.7	0
141	Why do schizophrenic patients hallucinate?. Behavioral and Brain Sciences, 2003, 26, 101-103.	0.7	0
142	Synchronous dynamics for cognitive coordination: But how?. Behavioral and Brain Sciences, 2003, 26, 106-107.	0.7	0
143	Guarding against over-inclusive notions of "context†Psycholinguistic and electrophysiological studies of specific context functions in schizophrenia. Behavioral and Brain Sciences, 2003, 26, 108-109.	0.7	5
144	Cognitive coordination deficits: A necessary but not sufficient factor in the development of schizophrenia. Behavioral and Brain Sciences, 2003, 26, 89-90.	0.7	0

#	Article	IF	Citations
145	Peeling the onion: NMDA dysfunction as a unifying model in schizophrenia. Behavioral and Brain Sciences, 2003, 26, 93-94.	0.7	10
146	Phenomenology, context, and self-experience in schizophrenia. Behavioral and Brain Sciences, 2003, 26, 104-105.	0.7	2
147	Schizophrenic cognition: Taken out of context?. Behavioral and Brain Sciences, 2003, 26, 91-91.	0.7	4
148	Schizophrenia: Putting context in context. Behavioral and Brain Sciences, 2003, 26, 98-99.	0.7	16
149	NMDA-receptor hypofunction versus excessive synaptic elimination as models of schizophrenia. Behavioral and Brain Sciences, 2003, 26, 92-92.	0.7	0
150	Psychoses of epilepsy. , 2004, , 547-565.		3
151	Amphetamine-Induced Fos is Reduced in Limbic Cortical Regions but not in the Caudate or Accumbens in a Genetic Model of NMDA Receptor Hypofunction. Neuropsychopharmacology, 2004, 29, 2180-2188.	5.4	32
152	Adenosine A1 Receptor Agonists Block the Neuropathological Changes in Rat Retrosplenial Cortex after Administration of the NMDA Receptor Antagonist Dizocilpine. Neuropsychopharmacology, 2004, 29, 544-550.	5.4	15
153	Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology, 2004, 29, 1259-1269.	5.4	232
154	Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists. Neuropsychopharmacology, 2004, 29, 300-307.	5.4	100
155	NMDA Receptor Function, Neuroplasticity, and the Pathophysiology of Schizophrenia. International Review of Neurobiology, 2004, 59, 491-515.	2.0	115
156	Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamus in Schizophrenia and Bipolar Disorder. Neuropsychopharmacology, 2004, 29, 1353-1362.	5.4	150
157	Glutamate as a therapeutic target in psychiatric disorders. Molecular Psychiatry, 2004, 9, 984-997.	7.9	457
158	Transitive inference in schizophrenia: impairments in relational memory organization. Schizophrenia Research, 2004, 68, 235-247.	2.0	129
159	Effects of d-cycloserine on negative symptoms in schizophrenia. Schizophrenia Research, 2004, 71, 239-248.	2.0	88
160	Schizophrenia as a Disorder of Neuroplasticity. International Review of Neurobiology, 2004, 59, 19-45.	2.0	64
161	Regulation of affect by the lateral septum: implications for neuropsychiatry. Brain Research Reviews, 2004, 46, 71-117.	9.0	418
162	Density of Glutamic Acid Decarboxylase 67 Messenger RNA–ContainingNeurons That Express the N-Methyl-D-AspartateReceptor Subunit NR2A in the Anterior Cingulate Cortex in Schizophreniaand Bipolar Disorder. Archives of General Psychiatry, 2004, <u>61, 649</u> .	12.3	382

#	Article	IF	CITATIONS
163	Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Molecular Psychiatry, 2005, 10, 275-287.	7.9	111
164	Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry, 2005, 10, 79-104.	7.9	867
165	Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. European Journal of Pharmacology, 2005, 519, 114-117.	3.5	128
166	Functional imaging evidence of the relationship between recurrent psychotic episodes and neurodegenerative course in schizophrenia. Psychiatry Research - Neuroimaging, 2005, 139, 219-228.	1.8	26
167	Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of d-cycloserine. Psychiatry Research - Neuroimaging, 2005, 138, 23-31.	1.8	43
168	Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. Journal of Neuroscience Research, 2005, 81, 284-292.	2.9	47
169	Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. Psychopharmacology, 2005, 180, 366-376.	3.1	74
170	Review of the use of Topiramate for treatment of psychiatric disorders. , 2005, 4, 5.		115
171	Characterization of medial septal glutamatergic neurons and their projection to the hippocampus. Synapse, 2005, 58, 151-164.	1.2	165
172	Modulation of Striatal Dopamine Release by Glycine Transport Inhibitors. Neuropsychopharmacology, 2005, 30, 649-656.	5.4	43
173	The Role of Cytokine Network in the Pathophysiology of Schizophrenia. Current Psychiatry Reviews, 2005, 1, 123-131.	0.9	4
174	Dopamine is not Required for the Hyperlocomotor Response to NMDA Receptor Antagonists. Neuropsychopharmacology, 2005, 30, 1324-1333.	5.4	89
175	Sarcosine or D-Serine Add-on Treatment for Acute Exacerbation of Schizophrenia. Archives of General Psychiatry, 2005, 62, 1196.	12.3	263
176	Imaging Frontostriatal Function in Ultra-High-Risk, Early, and Chronic Schizophrenia During Executive Processing. Archives of General Psychiatry, 2005, 62, 254.	12.3	186
177	Interactions of Lead Exposure and Stress: Implications for Cognitive Dysfunction. International Review of Research in Mental Retardation, 2005, 30, 87-139.	0.7	3
178	No Association between the Ionotropic Glutamate Receptor Kainate 3 Gene ser310ala Polymorphism and Schizophrenia. Neuropsychobiology, 2005, 51, 211-213.	1.9	13
179	Lowered DHEA-S plasma levels in adult individuals with autistic disorder. European Neuropsychopharmacology, 2005, 15, 305-309.	0.7	50
180	D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry, 2005, 57, 577-585.	1.3	365

#	Article	IF	CITATIONS
181	Diagnosis-Related Regional Gray Matter Loss Over Two Years in First Episode Schizophrenia and Bipolar Disorder. Biological Psychiatry, 2005, 58, 713-723.	1.3	208
182	D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia. Biological Psychiatry, 2006, 59, 230-234.	1.3	310
183	Significant Association Between the Genetic Variations in the 5′ End of the N-Methyl-D-Aspartate Receptor Subunit Gene GRIN1 and Schizophrenia. Biological Psychiatry, 2006, 59, 747-753.	1.3	59
184	Magnocellular contributions to impaired motion processing in schizophrenia. Schizophrenia Research, 2006, 82, 1-8.	2.0	133
185	No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population. Schizophrenia Research, 2006, 88, 260-264.	2.0	31
186	Significant linkage and association between a functional (CT)n polymorphism in promoter of the N-methyl-d-aspartate receptor subunit gene (GRIN2A) and schizophrenia. Neuroscience Letters, 2006, 409, 80-82.	2.1	46
187	Glycine Transporter Inhibitors as Therapeutic Agents for Schizophrenia. Recent Patents on CNS Drug Discovery, 2006, 1, 43-53.	0.9	32
188	Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia. Synapse, 2006, 60, 585-598.	1.2	104
189	LY404187: A Novel Positive Allosteric Modulator of AMPA Receptors. CNS Neuroscience & Therapeutics, 2002, 8, 255-282.	4.0	83
190	LY503430: Pharmacology, Pharmacokinetics, and Effects in Rodent Models of Parkinson's Disease. CNS Neuroscience & Therapeutics, 2005, 11, 77-96.	4.0	40
191	Sarcosine based indandione hGlyT1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1388-1391.	2.2	15
192	Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacology Biochemistry and Behavior, 2006, 84, 259-265.	2.9	23
193	Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 762-767.	7.1	115
194	Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man. Journal of Psychopharmacology, 2007, 21, 321-337.	4.0	26
195	NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons. Journal of Neuroscience, 2007, 27, 11496-11500.	3.6	1,063
196	Phencyclidine-Induced Cognitive Deficits in Mice are Improved by Subsequent Subchronic Administration of Fluvoxamine: Role of Sigma-1 Receptors. Neuropsychopharmacology, 2007, 32, 514-521.	5.4	123
197	Why is d-serine nephrotoxic and α-aminoisobutyric acid protective?. American Journal of Physiology - Renal Physiology, 2007, 293, F382-F390.	2.7	61
198	Progressive and Interrelated Functional and Structural Evidence of Post-Onset Brain Reduction in Schizophrenia. Archives of General Psychiatry, 2007, 64, 521.	12.3	345

#	ARTICLE	IF	CITATIONS
199	Schizophrenia Susceptibility Genes: in Search of A Molecular Logic and Novel Drug Targets for A Devastating Disorder. International Review of Neurobiology, 2007, 78, 397-422.	2.0	14
200	Abnormal Glutamate Receptor Expression in the Medial Temporal Lobe in Schizophrenia and Mood Disorders. Neuropsychopharmacology, 2007, 32, 1888-1902.	5.4	368
201	Neural Synchrony in Schizophrenia: From Networks to New Treatments. Schizophrenia Bulletin, 2007, 33, 848-852.	4.3	115
202	Minocycline Attenuates Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Administration of the NMDA Receptor Antagonist Dizocilpine. Neuropsychopharmacology, 2007, 32, 2004-2010.	5.4	95
204	Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. International Clinical Psychopharmacology, 2007, 22, 249-267.	1.7	46
205	Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 697-702.	4.8	95
206	Chronic phencyclidine administration reduces the expression and editing of specific glutamate receptors in rat prefrontal cortex. Experimental Neurology, 2007, 208, 54-62.	4.1	26
207	Possible role for interactions between 5-lipoxygenase (5-LOX) and AMPA GluR1 receptors in depression and in antidepressant therapy. Medical Hypotheses, 2007, 69, 1076-1079.	1.5	4
208	Neurosteroids in child and adolescent psychopathology. European Neuropsychopharmacology, 2007, 17, 157-164.	0.7	26
210	Glutamate and Schizophrenia: Phencyclidine, Nâ€Methylâ€dâ€Aspartate Receptors, and Dopamine–Glutamate Interactions. International Review of Neurobiology, 2007, 78, 69-108.	2.0	463
211	SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia. Neuropsychopharmacology, 2007, 32, 17-34.	5.4	239
212	Positive Allosteric Modulation of Metabotropic Glutamate 5 (mGlu5) Receptors Reverses N-Methyl-D-Aspartate Antagonist-Induced Alteration of Neuronal Firing in Prefrontal Cortex. Biological Psychiatry, 2007, 62, 739-746.	1.3	99
214	<scp>d</scp> â€Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. European Journal of Neuroscience, 2007, 26, 1657-1669.	2.6	158
215	Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes, Brain and Behavior, 2007, 6, 677-687.	2.2	157
216	Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Research, 2007, 1154, 154-162.	2.2	68
217	Hippocampal abnormalities and memory deficits: New evidence of a strong pathophysiological link in schizophrenia. Brain Research Reviews, 2007, 54, 92-112.	9.0	155
218	Volume reduction of the left planum temporale gray matter associated with long duration of untreated psychosis in schizophrenia: A preliminary report. Psychiatry Research - Neuroimaging, 2007, 154, 209-219.	1.8	63
219	Increased inhibitory input to CA1 pyramidal cells alters hippocampal gamma frequency oscillations in the MK-801 model of acute psychosis. Neurobiology of Disease, 2007, 25, 545-552.	4.4	24

#	Article	IF	CITATIONS
220	Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Δ9-tetrahydrocannabinol. Psychopharmacology, 2007, 192, 325-336.	3.1	161
221	Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. Psychopharmacology, 2007, 192, 27-38.	3.1	26
222	Functional reactivity of the dopaminergic system following acute and chronic ketamine treatments. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378, 117-124.	3.0	2
223	The biochemical womb of schizophrenia: A review. Indian Journal of Clinical Biochemistry, 2008, 23, 307-327.	1.9	15
224	Inhibition of vesicular glutamate storage and exocytotic release by Rose Bengal. Journal of Neurochemistry, 2008, 77, 34-42.	3.9	4
225	Differential activation patterns of occipital and prefrontal cortices during motion processing: Evidence from normal and schizophrenic brains. Cognitive, Affective and Behavioral Neuroscience, 2008, 8, 293-303.	2.0	49
226	Replication of linkage on chromosome 7q22 and association of the regional Reelin gene with working memory in schizophrenia families. Molecular Psychiatry, 2008, 13, 673-684.	7.9	91
227	Increased truncated TrkB receptor expression and decreased BDNF/TrkB signaling in the frontal cortex of reeler mouse model of schizophrenia. Schizophrenia Research, 2008, 100, 325-333.	2.0	32
228	Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophrenia Research, 2008, 103, 71-82.	2.0	114
229	Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophrenia Research, 2008, 104, 108-120.	2.0	100
230	Genetic associations with schizophrenia: Meta-analyses of 12 candidate genes. Schizophrenia Research, 2008, 104, 96-107.	2.0	154
231	Altered Center-Surround Motion Inhibition in Schizophrenia. Biological Psychiatry, 2008, 64, 74-77.	1.3	42
232	N-Methyl-D-Aspartate Receptor and Calbindin-Containing Neurons in the Anterior Cingulate Cortex in Schizophrenia and Bipolar Disorder. Biological Psychiatry, 2008, 64, 803-809.	1.3	46
233	Characterization of interactions between phencyclidine and amphetamine in rodent prefrontal cortex and striatum: Implications in NMDA/glycine-site-mediated dopaminergic dysregulation and dopamine transporter function. Neurochemistry International, 2008, 52, 119-129.	3.8	27
234	DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. Neuroscience Letters, 2008, 440, 150-154.	2.1	15
235	Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: Development of a selective α7 nicotinic acetylcholine receptor agonist strategy. European Neuropsychopharmacology, 2008, 18, 147-151.	0.7	11
236	Repeated low dose of phencyclidine administration impairs spatial learning in mice: Blockade by clozapine but not by haloperidol. European Neuropsychopharmacology, 2008, 18, 486-497.	0.7	29
237	In vivo occipital–frontal temperature-gradient in schizophrenia patients and its possible association with psychopathology: A magnetic resonance spectroscopy study. European Neuropsychopharmacology, 2008, 18, 557-564.	0.7	11

#	Article	IF	CITATIONS
238	Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. Schizophrenia Research, 2008, 102, 283-294.	2.0	37
239	Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection. Pharmacological Reviews, 2008, 60, 358-403.	16.0	213
240	Chlorpromazine oligomer is a potentially active substance that inhibits human D-amino acid oxidase, product of a susceptibility gene for schizophrenia. Journal of Enzyme Inhibition and Medicinal Chemistry, 2008, 23, 901-911.	5.2	31
241	Prolonged Exposure to NMDAR Antagonist Suppresses Inhibitory Synaptic Transmission in Prefrontal Cortex. Journal of Neurophysiology, 2008, 100, 959-965.	1.8	101
242	Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting. Frontiers in Neural Circuits, 2009, 3, 20.	2.8	99
243	Hyperdopaminergia and NMDA Receptor Hypofunction Disrupt Neural Phase Signaling. Journal of Neuroscience, 2009, 29, 8215-8224.	3.6	86
244	MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3507-3512.	7.1	265
245	Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem. Schizophrenia Bulletin, 2009, 35, 403-414.	4.3	121
246	Reduced Expression of the NMDA Receptor-Interacting Protein SynGAP Causes Behavioral Abnormalities that Model Symptoms of Schizophrenia. Neuropsychopharmacology, 2009, 34, 1659-1672.	5.4	106
247	Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors. Brain Research, 2009, 1279, 189-196.	2.2	63
248	Increased d-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. Journal of Neural Transmission, 2009, 116, 1657-1665.	2.8	31
249	Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes, Brain and Behavior, 2009, 8, 661-675.	2.2	147
250	Schizophrenia: genetics, prevention and rehabilitation. Acta Neuropsychiatrica, 2009, 21, 109-120.	2.1	9
251	Gestational methylazoxymethanol acetate administration: A developmental disruption model of schizophrenia. Behavioural Brain Research, 2009, 204, 306-312.	2.2	204
252	Neurophysiological and neurochemical animal models of schizophrenia: Focus on glutamateâ~†. Behavioural Brain Research, 2009, 204, 352-362.	2.2	59
253	A rodent model of schizophrenia derived from postmortem studies. Behavioural Brain Research, 2009, 204, 363-368.	2.2	16
254	Interaction between N-methyl-d-aspartic acid receptors and D1 dopamine receptors: An important mechanism for brain plasticity. Neuroscience, 2009, 158, 62-66.	2.3	48
255	Glutamatergic Approaches to the Conceptualization and Treatment of Schizophrenia. , 2009, , 39-89.		6

#	Article	IF	CITATIONS
256	Duration of Untreated Psychosis and Duration of Untreated Illness: New Vistas. CNS Spectrums, 2010, 15, 238-246.	1.2	55
258	Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics. Psychopharmacology, 2010, 212, 155-170.	3.1	48
259	Rose Bengal analogs and vesicular glutamate transporters (VGLUTs). Bioorganic and Medicinal Chemistry, 2010, 18, 6922-6933.	3.0	26
260	Group 5 metabotropic glutamate receptors: Role in modulating cortical activity and relevance to cognition. European Journal of Pharmacology, 2010, 639, 33-39.	3.5	64
261	Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nature Neuroscience, 2010, 13, 76-83.	14.8	675
262	The genetics of latent inhibition: studies of inbred and mutant mice. , 0, , 225-251.		2
263	Extracellular Matrix-Glial Abnormalities in the Amygdala and Entorhinal Cortex of Subjects Diagnosed With Schizophrenia. Archives of General Psychiatry, 2010, 67, 155.	12.3	246
264	The Stanley Neuropathology Consortium Integrative Database: a Novel, Web-Based Tool for Exploring Neuropathological Markers in Psychiatric Disorders and the Biological Processes Associated with Abnormalities of Those Markers. Neuropsychopharmacology, 2010, 35, 473-482.	5.4	75
265	Reinforcement Ambiguity and Novelty Do Not Account for Transitive Inference Deficits in Schizophrenia. Schizophrenia Bulletin, 2010, 36, 1187-1200.	4.3	27
266	Gamma and Delta Neural Oscillations and Association with Clinical Symptoms under Subanesthetic Ketamine. Neuropsychopharmacology, 2010, 35, 632-640.	5.4	238
267	A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia. International Journal of Neuropsychopharmacology, 2010, 13, 451.	2.1	159
268	Corticosteroid and neurosteroid dysregulation in an animal model of autism, BTBR mice. Physiology and Behavior, 2010, 100, 264-267.	2.1	45
269	Auditory hallucinations and the P3a: Attention-switching to speech in schizophrenia. Biological Psychology, 2010, 85, 417-423.	2.2	33
270	DAOAvariants and schizophrenia: Influence on diagnosis and treatment outcomes. International Journal of Psychiatry in Clinical Practice, 2011, 15, 303-310.	2.4	4
271	Global White Matter Abnormalities in Schizophrenia: A Multisite Diffusion Tensor Imaging Study. Schizophrenia Bulletin, 2011, 37, 222-232.	4.3	113
272	Glutamatergic Gene Expression Is Specifically Reduced in Thalamocortical Projecting Relay Neurons in Schizophrenia. Biological Psychiatry, 2011, 70, 646-654.	1.3	45
273	Toward Personalized Medicine in the Neuropsychiatric Field. International Review of Neurobiology, 2011, 101, 329-349.	2.0	19
274	Endosomal trafficking of AMPA receptors in frontal cortex of elderly patients with schizophrenia. Schizophrenia Research, 2011, 130, 260-265.	2.0	16

		CITATION REI	PORT	
#	Article		IF	CITATIONS
275	Genetically Engineered Mice for Schizophrenia Research. Neuromethods, 2011, , 231-242.		0.3	0
276	Downregulated Kynurenine 3-Monooxygenase Gene Expression and Enzyme Activity in Schizophr and Genetic Association With Schizophrenia Endophenotypes. Archives of General Psychiatry, 20 665.	enia 11, 68,	12.3	141
277	Declarative memory deficits and schizophrenia: Problems and prospects. Neurobiology of Learnin and Memory, 2011, 96, 544-552.	g	1.9	41
278	In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mi and conscious monkeys. Nuclear Medicine and Biology, 2011, 38, 517-527.	се	0.6	12
279	Altered levels of glutamatergic receptors and Na+/K+ ATPase-α1 in the prefrontal cortex of subjective with schizophrenia. Schizophrenia Research, 2011, 128, 7-14.	rts	2.0	67
280	Alteration in the plasma concentration of a DAAO inhibitor, 3-methylpyrazole-5-carboxylic acid, in ketamine-treated rats and the influence on the pharmacokinetics of plasma D-tryptophan. Procee of the Japan Academy Series B: Physical and Biological Sciences, 2011, 87, 641-648.	the dings	3.8	1
281	A novel mutation in the aristaless domain of the ARX gene leads to Ohtahara syndrome, global developmental delay, and ambiguous genitalia in males and neuropsychiatric disorders in females Epilepsia, 2011, 52, 984-992.		5.1	26
282	Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Ger Brain and Behavior, 2011, 10, 210-222.	ies,	2.2	103
283	Discordant behavioral effects of psychotomimetic drugs in mice with altered NMDA receptor function. Psychopharmacology, 2011, 213, 143-153.		3.1	13
284	Effects of low-dose d-serine on recognition and working memory in mice. Psychopharmacology, 2 218, 461-470.	011,	3.1	79
285	<i>In vivo</i> and <i>ex vivo</i> evidence for ketamineâ€induced hyperglutamatergic activity in cerebral cortex of the rat: Potential relevance to schizophrenia. NMR in Biomedicine, 2011, 24, 1235-1242.	:he	2.8	59
286	Oxidative stress in schizophrenia: An integrated approach. Neuroscience and Biobehavioral Review 2011, 35, 878-893.	WS,	6.1	375
287	Duration of illness and duration of untreated illness in relation to drug response in psychiatric disorders. Neuropsychiatry, 2011, 1, 81-90.		0.4	31
288	Translating Glutamate: From Pathophysiology to Treatment. Science Translational Medicine, 201 102mr2.	1, 3,	12.4	147
289	Overexpression of Reelin Prevents the Manifestation of Behavioral Phenotypes Related to Schizophrenia and Bipolar Disorder. Neuropsychopharmacology, 2011, 36, 2395-2405.		5.4	85
290	Intracerebral adult stem cells transplantation increases brain-derived neurotrophic factor levels and protects against phencyclidine-induced social deficit in mice. Translational Psychiatry, 2011, e61-e61.	1,	4.8	21
291	Increased expression of receptor phosphotyrosine phosphatase-β/ζ is associated with molecular cellular, behavioral and cognitive schizophrenia phenotypes. Translational Psychiatry, 2011, 1, e8	-e8.	4.8	37
292	NMDAR antagonist action in thalamus imposes delta oscillations on the hippocampus. Journal of Neurophysiology, 2012, 107, 3181-3189.		1.8	89

#	Article	IF	CITATIONS
293	Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator. Neuropsychopharmacology, 2012, 37, 1057-1066.	5.4	90
294	NAAG, NMDA Receptor and Psychosis. Current Medicinal Chemistry, 2012, 19, 1360-1364.	2.4	41
295	Recent Advances in Targeting the Ionotropic Glutamate Receptors in Treating Schizophrenia. Current Pharmaceutical Biotechnology, 2012, 13, 1535-1542.	1.6	12
296	The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development. Current Pharmaceutical Biotechnology, 2012, 13, 1500-1512.	1.6	45
297	Capturing the Angel in "Angel Dust": Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans. Schizophrenia Bulletin, 2012, 38, 942-949.	4.3	204
298	Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia. Schizophrenia Bulletin, 2012, 38, 958-966.	4.3	268
299	GABAergic interneuron origin of schizophrenia pathophysiology. Neuropharmacology, 2012, 62, 1574-1583.	4.1	403
300	Extracellular matrix abnormalities in schizophrenia. Neuropharmacology, 2012, 62, 1584-1597.	4.1	159
301	Role of the anterior thalamic nucleus in the motor hyperactivity induced by systemic MK-801 administration in rats. Neuropharmacology, 2012, 62, 2440-2446.	4.1	15
302	NMDA Receptor and Schizophrenia: A Brief History. Schizophrenia Bulletin, 2012, 38, 920-926.	4.3	329
303	Longitudinal loss of gray matter volume in patients with first-episode schizophrenia: DARTEL automated analysis and ROI validation. NeuroImage, 2012, 59, 986-996.	4.2	129
304	Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia. European Neuropsychopharmacology, 2012, 22, 902-910.	0.7	13
305	Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder?. Molecular Psychiatry, 2012, 17, 669-681.	7.9	78
306	Hippocampal temporal-parietal junction interaction in the production of psychotic symptoms: a framework for understanding the schizophrenic syndrome. Frontiers in Human Neuroscience, 2012, 6, 180.	2.0	37
307	MicroRNAs in Neurotoxicity. Journal of Toxicology, 2012, 2012, 1-15.	3.0	36
308	Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry, 2012, 17, 1206-1227.	7.9	479
309	Tractâ€based magnetic resonance spectroscopy of the cingulum bundles at 7 T. Human Brain Mapping, 2012, 33, 1503-1511.	3.6	10
310	Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacology Biochemistry and Behavior, 2012, 100, 665-677.	2.9	132

#	Article	IF	CITATIONS
311	Modulation of NMDA receptor function as a treatment for schizophrenia. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5034-5044.	2.2	28
312	The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders. Psychopharmacology, 2013, 229, 415-434.	3.1	117
313	Effects of AS2586114, a soluble epoxide hydrolase inhibitor, on hyperlocomotion and prepulse inhibition deficits in mice after administration of phencyclidine. Pharmacology Biochemistry and Behavior, 2013, 110, 98-103.	2.9	14
314	A systematic review of the effects of NMDA receptor antagonists on oscillatory activity recorded in vivo. Journal of Psychopharmacology, 2013, 27, 972-986.	4.0	69
315	Autoimmune-induced glutamatergic receptor dysfunctions: Conceptual and psychiatric practice implications. European Neuropsychopharmacology, 2013, 23, 1659-1671.	0.7	21
316	Duration of untreated illness (DUI) and schizophrenia sub-types: A collaborative study between the universities of Milan and Moscow. International Journal of Social Psychiatry, 2013, 59, 765-770.	3.1	9
317	MK-801 disrupts and nicotine augments 40ÂHz auditory steady state responses in the auditory cortex of the urethane-anesthetized rat. Neuropharmacology, 2013, 73, 1-9.	4.1	41
318	Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 367-377.	3.2	177
319	Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in anterior cingulate cortex in schizophrenia. Schizophrenia Research, 2013, 147, 32-38.	2.0	23
320	Afferent Drive of Medial Prefrontal Cortex by Hippocampus and Amygdala is Altered in MAM-Treated Rats: Evidence for Interneuron Dysfunction. Neuropsychopharmacology, 2013, 38, 1871-1880.	5.4	24
321	Neurophysiological analysis of schizophrenia based on dysfunction of the glutamatergic system using a tripartite synapse model. , 2013, , .		2
322	Spatial Characteristics of White Matter Abnormalities in Schizophrenia. Schizophrenia Bulletin, 2013, 39, 1077-1086.	4.3	36
323	Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator <scp>CDPPB</scp> on phencyclidineâ€induced cognitive deficits in mice. Fundamental and Clinical Pharmacology, 2013, 27, 483-488.	1.9	44
324	Metabolic Maturation of the Human Brain From Birth Through Adolescence: Insights From In Vivo Magnetic Resonance Spectroscopy. Cerebral Cortex, 2013, 23, 2944-2955.	2.9	131
325	Alternative pharmacologic targets for the treatment of schizophrenia. Current Opinion in Psychiatry, 2013, 26, 158-165.	6.3	23
326	Can Long-Term Outcomes Be Improved by Shortening the Duration of Untreated Illness in Psychiatric Disorders? A Conceptual Framework. Psychopathology, 2013, 46, 14-21.	1.5	85
328	D-serine as a gliotransmitter and its roles in brain development and disease. Frontiers in Cellular Neuroscience, 2013, 7, 39.	3.7	89
330	Neurobiological determinants of cognition. , 0, , 176-192.		0

ARTICLE IF CITATIONS Two grams of sarcosine in schizophrenia & amp; ndash; is it too much? A potential role of glutamate-331 2.2 14 serotonin interaction. Neuropsychiatric Disease and Treatment, 2014, 10, 263. Involvement of Glutamate in Learning and Memory., 2014, , 63-77. 9 Meta-analyses of 10 polymorphisms associated with the risk of schizophrenia. Biomedical Reports, 333 2.0 20 2014, 2, 729-736. Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in 334 39 schizophrenia. Schizophrenia Research, 2014, 160, 80-87. Studying the effect of dysregulation of NMDA receptors function in schizophrenia., 2014,,. 335 3 Evidence of Glutamatergic Dysfunction in the Pathophysiology of Schizophrenia., 2014, , 265-294. Association analysis of the GRM8 gene with schizophrenia in the Uygur Chinese population. Hereditas, 337 1.4 9 2014, 151, 140-144. New therapeutic approaches for treatment-resistant schizophrenia: A look to the future. Journal of 338 3.1 57 Psychiatric Research, 2014, 58, 1-6. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opinion on Therapeutic 339 3.4 101 Targets, 2014, 18, 1049-1063. 340 Altered serine/threonine kinase activity in schizophrenia. Brain Research, 2014, 1568, 42-54. 2.2 Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models. Science, 2014, 341 12.6 107 344, 1178-1182. Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with 343 2.2 schizophrenia: a case study. Neuropsychiatric Disease and Treatment, 2015, 11, 533. Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. 344 4.1 24 International Journal of Molecular Sciences, 2015, 16, 24475-24489. Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia. Nutrients, 2015, 7, 8767-8782. 345 4.1 Overview of Glutamatergic Dysregulation in Central Pathologies. Biomolecules, 2015, 5, 3112-3141. 346 4.0 87 Availability of N-Methyl-d-Aspartate Receptor Coagonists Affects Cocaine-Induced Conditioned Place 347 Preference and Locomotor Sensitization: Implications for Comorbid Schizophrenia and Substance Abuse. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 465-470. 348 Major diencephalic inputs to the hippocampus. Progress in Brain Research, 2015, 219, 121-144. 1.4 65 Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after 349 2.1 administration of phencyclidine. Acta Neuropsychiatrica, 2015, 27, 159-167.

#	Article	IF	CITATIONS
350	Is duration of illness really influencing outcome in major psychoses?. Nordic Journal of Psychiatry, 2015, 69, 1685-1699.	1.3	46
351	Brain Rhythms Connect Impaired Inhibition to Altered Cognition in Schizophrenia. Biological Psychiatry, 2015, 77, 1020-1030.	1.3	74
352	The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Annals of the New York Academy of Sciences, 2015, 1338, 38-57.	3.8	198
353	Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Molecular Psychiatry, 2015, 20, 1151-1160.	7.9	78
354	Clinical Correlates of Superior Temporal Gyrus Volume Abnormalities in Antipsychotic-NaÃ ⁻ ve Schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 2015, 27, e128-e133.	1.8	10
355	The neuromediator mechanisms of the cognitive deficit in schizophrenia. Neurochemical Journal, 2015, 9, 186-200.	0.5	2
356	Aggrecan and chondroitin-6-sulfate abnormalities in schizophrenia and bipolar disorder: a postmortem study on the amygdala. Translational Psychiatry, 2015, 5, e496-e496.	4.8	116
357	Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia. Neuroscience Letters, 2015, 606, 7-12.	2.1	28
358	Allocentric spatial navigation impairment in schizophrenic subject: A model-based study. , 2015, , .		0
359	Astrocytes as Pharmacological Targets in the Treatment of Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 423-443.	0.7	17
360	Influence of Genetic Variants of the N-Methyl-D-Aspartate Receptor on Emotion and Social Behavior in Adolescents. Neural Plasticity, 2016, 2016, 1-8.	2.2	11
361	Hormones and Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 463-480.	0.7	1
362	lloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. Core Evidence, 2016, Volume 11, 49-61.	4.7	18
363	In Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric Disorders. Neural Plasticity, 2016, 2016, 1-23.	2.2	95
364	N-Methyl D-Aspartate Receptor Antagonist Kynurenic Acid Affects Human Cortical Development. Frontiers in Neuroscience, 2016, 10, 435.	2.8	31
365	Pharmacological Treatment of Schizophrenia:. Clinical Neuropsychopharmacology and Therapeutics, 2016, 7, 1-8.	0.3	4
366	Targeting Cognitive Deficits in Schizophrenia via GABAA Receptors. , 2016, , 149-164.		0
367	Gamma band oscillations. Current Opinion in Psychiatry, 2016, 29, 202-210.	6.3	105

ARTICLE IF CITATIONS Diverse roles for ionotropic glutamate receptors on inhibitory interneurons in developing and adult 368 2.9 77 brain. Journal of Physiology, 2016, 594, 5471-5490. Electrophysiological Endophenotypes for Schizophrenia. Harvard Review of Psychiatry, 2016, 24, 2.1 129-147 Targeting glutamate to treat schizophrenia: lessons from recent clinical studies. 370 3.1 22 Psychopharmacology, 2016, 233, 2425-2428. Effects of the inducible nitric oxide synthase inhibitor aminoguanidine in two different rat models of 371 schizophrenia. Behavioural Brain Research, 2016, 309, 14-21. Modulation of glycine sites enhances social memory in rats using PQQ combined with d-serine. 372 2.2 4 Behavioural Brain Research, 2016, 308, 217-221. Decreased CB receptor binding and cannabinoid signaling in three brain regions of a rat model of schizophrenia. Neuroscience Letters, 2016, 633, 87-93. 2.1 Proteomics and molecular tools for unveiling missing links in the biochemical understanding of 374 1.6 14 schizophrenia. Proteomics - Clinical Applications, 2016, 10, 1148-1158. Neuregulin-1 and schizophrenia in the genome-wide association study era. Neuroscience and 6.1 68 Biobehavioral Reviews, 2016, 68, 387-409. 376 Novel Targets for Drug Treatment in Psychiatry., 2016, , 601-654. 0 The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like 3.1 behaviour in rats. Psychopharmacology, 2016, 233, 1045-1054. Mitochondrial impairment, apoptosis and autophagy in a rat brain as immediate and long-term effects of perinatal phencyclidine treatment â€" influence of restraint stress. Progress in 378 4.8 26 Neuro-Psychopharmacology and Biological Psychiatry, 2016, 66, 87-96. Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of 379 1.3 103 Schizophrenia. Biological Psychiatry, 2016, 79, 716-726. The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 380 2.6 13 knockout mice. European Journal of Neuroscience, 2017, 45, 912-921. Immune activation in lactating dams alters sucklings' brain cytokines and produces non-overlapping behavioral deficits in adult female and male offspring: A novel neurodevelopmental model of sex-specific psychopathology. Brain, Behavior, and Immunity, 2017, 63, 35-49. 4.1 382 Classics in Chemical Neuroscience: Aripiprazole. ACS Chemical Neuroscience, 2017, 8, 1135-1146. 3.5 80 MK-801-Treated Oligodendrocytes as a Cellular Model to Study Schizophrenia. Advances in Experimental Medicine and Biólogy, 2017, 974, 269-277. Phenotyping in Precision Medicine., 2017, , 55-77. 384 4 Hippocampal GABAergic Inhibitory Interneurons. Physiological Reviews, 2017, 97, 1619-1747. 28.8 601

#	Article	IF	CITATIONS
386	Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats. Psychopharmacology, 2017, 234, 3027-3036.	3.1	6
387	Traits and Biomarkers for Addiction Risk in Schizophrenia. Current Addiction Reports, 2017, 4, 14-24.	3.4	10
388	Increased serum G72 protein levels in patients with schizophrenia: a potential candidate biomarker. Acta Neuropsychiatrica, 2017, 29, 80-86.	2.1	11
389	Synthesis and biological evaluation of novel flavanone derivatives as potential antipsychotic agents. Chemical Biology and Drug Design, 2017, 89, 353-364.	3.2	6
390	Potential synergistic action of 19 schizophrenia risk genes in the thalamus. Schizophrenia Research, 2017, 180, 64-69.	2.0	11
391	Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research. Frontiers in Pharmacology, 2017, 8, 399.	3.5	25
392	Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway. International Journal of Molecular Sciences, 2017, 18, 1416.	4.1	11
393	Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in <i>N</i> -Methyl-d-Aspartate Receptor Antagonist–Induced Rat Models of Schizophrenia. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 179-188.	2.5	23
394	d-Serine administration affects nitric oxide synthase 1 adaptor protein and DISC1 expression in sex-specific manner. Molecular and Cellular Neurosciences, 2018, 89, 20-32.	2.2	8
395	Presynaptic Effects of N-Methyl-D-Aspartate Receptors Enhance Parvalbumin Cell–Mediated Inhibition of Pyramidal Cells in Mouse Prefrontal Cortex. Biological Psychiatry, 2018, 84, 460-470.	1.3	28
396	Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach. Scientific Reports, 2018, 8, 2894.	3.3	31
397	Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the <scp>PULSAR</scp> study). Human Psychopharmacology, 2018, 33, e2652.	1.5	11
398	Defects in Bioenergetic Coupling in Schizophrenia. Biological Psychiatry, 2018, 83, 739-750.	1.3	67
399	NEUROTRANSMITTER AND BRAIN PARTS INVOLVED IN SCHIZOPHRENIA. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 4.	0.3	6
400	The Role of Serine Racemase in the Pathophysiology of Brain Disorders. Advances in Pharmacology, 2018, 82, 35-56.	2.0	36
401	Quercetin Reduces Cortical GABAergic Transmission and Alleviates MK-801-Induced Hyperactivity. EBioMedicine, 2018, 34, 201-213.	6.1	22
402	Glutamate Concentration in the Superior Temporal Sulcus Relates to Neuroticism in Schizophrenia. Frontiers in Psychology, 2018, 9, 578.	2.1	1
403	Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study). Psychiatry Research, 2018, 268, 447-453.	3.3	15

#	Article	IF	CITATIONS
404	Defining the Role of Interneuron N-Methyl-D-Aspartate Receptors in Prefrontal Cortex Inhibition. Biological Psychiatry, 2018, 84, 399-400.	1.3	0
405	Is the History of Substance Abuse Correlated with Neuropsychiatric Disorders and Co-morbid HIV Infection? An Urban Population Study. Journal of Neurology and Neuroscience, 2018, 09, .	0.4	1
406	Cuprizone-treated mice, a possible model of schizophrenia, highlighting the simultaneous abnormalities of GABA, serine and glycine in hippocampus. Schizophrenia Research, 2019, 210, 326-328.	2.0	4
407	DNA damage and repair in neuropsychiatric disorders. What do we know and what are the future perspectives?. Mutagenesis, 2020, 35, 79-106.	2.6	14
408	Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia. Neuroscience and Biobehavioral Reviews, 2019, 107, 795-827.	6.1	17
409	A Natural Product with High Affinity to Sigma and 5-HT7 Receptors as Novel Therapeutic Drug for Negative and Cognitive Symptoms of Schizophrenia. Neurochemical Research, 2019, 44, 2536-2545.	3.3	11
410	Glutamate hypothesis in schizophrenia. Psychiatry and Clinical Neurosciences, 2019, 73, 204-215.	1.8	229
411	Preclinical characterization of AMPA receptor potentiator TAKâ€137 as a therapeutic drug for schizophrenia. Pharmacology Research and Perspectives, 2019, 7, e00479.	2.4	12
412	Ameliorating effects of berberine on MK-801-induced cognitive and motor impairments in a neonatal rat model of schizophrenia. Neuroscience Letters, 2019, 706, 151-157.	2.1	29
413	Biochemical Pathways Triggered by Antipsychotics in Human Oligodendrocytes: Potential of Discovering New Treatment Targets. Frontiers in Pharmacology, 2019, 10, 186.	3.5	12
414	Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress. Frontiers in Psychiatry, 2019, 10, 93.	2.6	51
415	The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts behavioural deficits induced by the NMDA receptor antagonist ketamine in rats. Neuropharmacology, 2019, 151, 74-83.	4.1	19
416	Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology, 2019, 33, 436-448.	4.0	33
417	Effects of sodium nitroprusside in the acute dizocilpine (MK-801) animal model of schizophrenia. Brain Research Bulletin, 2019, 147, 140-147.	3.0	9
418	Synaptic Plasticity Shapes Brain Connectivity: Implications for Network Topology. International Journal of Molecular Sciences, 2019, 20, 6193.	4.1	78
419	The Stanley Neuropathology Consortium Integrative Database (SNCID) for Psychiatric Disorders. Neuroscience Bulletin, 2019, 35, 277-282.	2.9	8
420	Could Dietary Glutamate Play a Role in Psychiatric Distress?. Neuropsychobiology, 2020, 79, 13-19.	1.9	21
421	Electoretinographic evidence of retinal ganglion cell-dependent function in schizophrenia. Schizophrenia Research, 2020, 219, 34-46.	2.0	14

#	Article	IF	CITATIONS
422	Characterization hiPSC-derived neural progenitor cells and neurons to investigate the role of NOS1AP isoforms in human neuron dendritogenesis. Molecular and Cellular Neurosciences, 2020, 109, 103562.	2.2	3
423	Translational neurophysiological biomarkers of N-methyl-d-aspartate receptor dysfunction in serine racemase knockout mice. Biomarkers in Neuropsychiatry, 2020, 2, 100019.	1.0	8
424	A role for endothelial NMDA receptors in the pathophysiology of schizophrenia. Schizophrenia Research, 2022, 249, 63-73.	2.0	9
425	Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?. Biomolecules, 2020, 10, 1134.	4.0	13
426	Are working memory and glutamate concentrations involved in earlyâ€ l ife stress and severity of psychosis?. Brain and Behavior, 2020, 10, e01616.	2.2	11
427	Disordered directional brain network interactions during learning dynamics in schizophrenia revealed by multivariate autoregressive models. Human Brain Mapping, 2020, 41, 3594-3607.	3.6	16
428	Post-translational protein modifications in schizophrenia. NPJ Schizophrenia, 2020, 6, 5.	3.6	38
429	Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology, 2020, 34, 495-505.	4.0	25
430	ALDH4A1 expression levels are elevated in postmortem brains of patients with schizophrenia and are associated with genetic variants in enzymes related to proline metabolism. Journal of Psychiatric Research, 2020, 123, 119-127.	3.1	8
431	Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction. Neuropharmacology, 2020, 168, 107998.	4.1	17
432	Glutamate and Dysconnection in the Salience Network: Neurochemical, Effective Connectivity, and Computational Evidence in Schizophrenia. Biological Psychiatry, 2020, 88, 273-281.	1.3	58
433	Frontal–striatal connectivity and positive symptoms of schizophrenia: implications for the mechanistic basis of prefrontal rTMS. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 3-15.	3.2	11
434	Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the doubleâ€blind randomized controlled PULSAR study). Human Psychopharmacology, 2021, 36, e2770.	1.5	1
435	Neurotransmitter Release of Reprogrammed Cells Using Electrochemical Detection Methods. Methods in Molecular Biology, 2021, 2352, 201-226.	0.9	2
436	Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease. International Journal of Molecular Sciences, 2021, 22, 4299.	4.1	14
437	Cannabidiol modulation of hippocampal glutamate in early psychosis. Journal of Psychopharmacology, 2021, 35, 814-822.	4.0	20
438	Brain proton magnetic resonance spectroscopy and neurodevelopment after preterm birth: a systematic review. Pediatric Research, 2022, 91, 1322-1333.	2.3	7
439	Pairing of neonatal phencyclidine exposure and acute adolescent stress in male rats as a novel developmental model of schizophrenia. Behavioural Brain Research, 2021, 409, 113308.	2.2	4

#	Article	IF	CITATIONS
440	Pharmaco-Magnetic Resonance as a Tool for Monitoring the Medication-Related Effects in the Brain May Provide Potential Biomarkers for Psychotic Disorders. International Journal of Molecular Sciences, 2021, 22, 9309.	4.1	4
441	N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study. Translational Psychiatry, 2021, 11, 425.	4.8	14
442	Schizophrenia as a Disorder of Developmentally Reduced Synaptic Connectivity. Archives of General Psychiatry, 2000, 57, 637-648.	12.3	595
443	ls NMDA Receptor Hypofunction in Schizophrenia Associated With a Primary Hyperglutamatergic State?. Archives of General Psychiatry, 2002, 59, 466-468.	12.3	34
444	The Neurochemistry of Schizophrenia. , 0, , 349-364.		4
446	Survey of Selective Neurotoxins. , 2014, , 3-67.		4
447	Excitotoxic Damage in Traumatic Brain Injury. , 2001, , 1-36.		9
448	Developmental models and hypothesis-driven early interventions in schizophrenia. , 2004, , 455-472.		1
450	<scp>d-</scp> Serine Added to Clozapine for the Treatment of Schizophrenia. American Journal of Psychiatry, 1999, 156, 1822-1825.	7.2	196
451	Involvement of the NMDA System in Learning and Memory. Frontiers in Neuroscience, 2006, , 37-48.	0.0	30
452	Glutamate Receptors in Schizophrenia and Antipsychotic Drugs. Handbooks of Pharmacology and Toxicology, 2000, , 121-136.	0.1	4
453	Neurexin-1 and Frontal Lobe White Matter: An Overlapping Intermediate Phenotype for Schizophrenia and Autism Spectrum Disorders. PLoS ONE, 2011, 6, e20982.	2.5	58
454	Ampa Receptor Subunit Expression in the Endoplasmic Reticulum in Frontal Cortex of Elderly Patients with Schizophrenia. PLoS ONE, 2012, 7, e39190.	2.5	14
456	Glycine Transport Inhibitors for the Treatment of Schizophrenia. Open Medicinal Chemistry Journal, 2010, 4, 10-19.	2.4	39
457	Effects of D-Amino Acid Oxidase Inhibitor on the Extracellular D-Alanine Levels and the Efficacy of D-Alanine on Dizocilpine-Induced Prepulse Inhibition Deficits in Mice. The Open Clinical Chemistry Journal, 2009, 2, 16-21.	0.7	26
458	Neurotransmission. Medical Psychiatry, 2007, , 81-100.	0.2	2
459	NMDA receptor function, memory, and brain aging. Dialogues in Clinical Neuroscience, 2000, 2, 219-232.	3.7	157
460	Topiramate in Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2013, 6, 186-196.	1.4	21

#	Article	IF	CITATIONS
461	Prenatal Complications, Genetic Vulnerability, and Schizophrenia: The New England Longitudinal Studies of Schizophrenia. Psychiatric Annals, 1999, 29, 151-156.	0.1	29
462	Neuromodulation of Attention in Schizophrenia. Psychiatric Annals, 1999, 29, 633-640.	0.1	1
463	Clutamatergic Augmentation Strategies for Cognitive Impairment in Schizophrenia. Psychiatric Annals, 1999, 29, 649-654.	0.1	3
464	Inflammation and Schizophrenia. Psychiatric Annals, 2018, 48, 237-243.	0.1	2
465	Glutamate Receptor Abnormalities in Schizophrenia: Implications for Innovative Treatments. Biomolecules and Therapeutics, 2012, 20, 1-18.	2.4	67
466	Diffusion Tensor Imaging Findings of White Matter Changes in First Episode Schizophrenia: A Systematic Review. Clinical Psychopharmacology and Neuroscience, 2012, 10, 13-24.	2.0	57
467	Effects of the Antioxidant Sulforaphane on Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Phencyclidine Administration. Clinical Psychopharmacology and Neuroscience, 2012, 10, 94-98.	2.0	42
468	A Selective Review of the Excitatory-Inhibitory Imbalance in Schizophrenia: Underlying Biology, Genetics, Microcircuits, and Symptoms. Frontiers in Cell and Developmental Biology, 2021, 9, 664535.	3.7	30
470	Neurotoxicity of NMDA antagonists: a glutamatergic theory of schizophrenia based on selective impairment of local inhibitory feedback circuits. Dialogues in Clinical Neuroscience, 2000, 2, 287-298.	3.7	5
471	Defining the Role of Specific Limbic Circuitry in the Pathophysiology of Schizophrenia and Bipolar Disorder. Neurobiological Foundation of Aberrant Behaviors, 2002, , 211-233.	0.2	0
472	Genetically Altered Mice as Models for Understanding Brain Disorders. Research and Perspectives in Neurosciences, 2003, , 65-84.	0.4	0
473	The Biology of Schizotaxia. , 2004, , 339-353.		1
474	Pharmakologische Beeinflussbarkeit von Verhaltensparametern in genetischen und Läons-induzierten Tiermodellen der Schizophrenie. , 2004, , 460-467.		0
475	The role of the immune system in the pathophysiology of schizophrenia. , 2005, , 37-42.		0
476	Methods for Evaluation of Positive Allosteric Modulators of Glutamate AMPA Receptors. Methods in Molecular Biology, 2007, 403, 37-57.	0.9	1
477	Biochemical alterations in schizophrenia. , 2009, , 128-144.		0
478	Biochemical alterations in schizophrenia. Medical Psychiatry, 2009, , 114-130.	0.2	0
479	Studying chemical and electrical neuronal dynamics as a platform for understanding schizophrenia. Journal of Coupled Systems and Multiscale Dynamics, 2013, 1, 405-427.	0.2	0

ARTICLE IF CITATIONS # The Hypothesis of <i>Hyperia</i> from the Perspective of Neuronal Plasticity. Open Journal 480 0.5 0 of Medical Psychology, 2016, 05, 17-26. The Glutamatergic System as Potential Clinical Biomarkers for Blood and Cerebrospinal Fluid 481 0.3 Monitoring. Neuromethods, 2018, , 507-521. 485 Neurochemical Transmission., 0,, 545-641. 0 Animal models of schizophrenia: a critical review. Journal of Psychiatry and Neuroscience, 2001, 26, 486 2.4 395-410. Semantics and N400: insights for schizophrenia. Journal of Psychiatry and Neuroscience, 2004, 29, 487 2.4 36 89-98. Expression profiles of schizophrenia susceptibility genes during human prefrontal cortical 488 2.4 development. Journal of Psychiatry and Neuroscience, 2009, 34, 450-8. Psychosocial disabilities in patients with schizophrenia. Iranian Journal of Public Health, 2012, 41, 493 0.5 10 116-21. A magnetic resonance spectroscopy study of the anterior cingulate cortex in youth with emotional 400 0.2 9 dysregulation. Israel Journal of Psychiatry, 2012, 49, 62-9. Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative 500 0 1.7 Review. Schizophrenia Bulletin Open, 2022, 3, . Present and future antipsychotic drugs: A systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspective. Pharmacological Research, 2022, 7.1 176, 106078. Glutamate and N-Acetylaspartate Alterations Observed in Early Phase Psychosis: A Systematic Review of Proton Magnetic Résonance Spectroscopy Studies. Psychiatry Research - Neuroimaging, 2022, 321, 502 0 1.8 111459. Concurrent anodal transcranial direct current stimulation (tDCS) with cognitive training to improve cognition in schizophrenia. Schizophrenia Research, 2022, 241, 184-186. Differential expression of miR-148b, miR-129-2 and miR-296 in animal models of schizophrenia-Relevance 504 4.1 14 to NMDA receptor hypofunction. Neuropharmacology, 2022, 210, 109024. A Case for Thalamic Mechanisms of Schizophrenia: Perspective From Modeling 22q11.2 Deletion 2.8 Syndrome. Frontiers in Neural Circuits, 2021, 15, 769969. Activation of A_{2B} adenosine receptor protects against demyelination in a mouse model of 506 2 1.8 schizophrenia. Experimental and Therapeutic Medicine, 2022, 23, 396. Aging-Associated Cognitive Decline is Reversed by D-Serine Supplementation. ENeuro, 2022, 9, 514 EŇEŬRO.0176-22.2022. Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From 516 4.0 15 Neurobiology to the Clinics. Biomolecules, 2022, 12, 909. Known and Unexplored Post-Translational Modification Pathways in Schizophrenia. Advances in 1.6 Experimental Medicine and Biology, 2022, , 75-87.

#	Article	IF	CITATIONS
519	Schizophrenia, Bipolar and Major Depressive Disorders: Overview of Clinical Features, Neurotransmitter Alterations, Pharmacological Interventions, and Impact of Oxidative Stress in the Disease Process. ACS Chemical Neuroscience, 2022, 13, 2784-2802.	3.5	15
521	Sonic hedgehog pathway as a new target of atypical antipsychotics: Revisiting of amisulpride and aripiprazole effects in a rat model of schizophrenia. Life Sciences, 2023, , 121366.	4.3	3
522	Children with Early-Onset Psychosis Have Increased Burden of Rare GRIN2A Variants. Genes, 2023, 14, 779.	2.4	2
523	Editorial: New insights into schizophrenia-related neural and behavioral phenotypes. Frontiers in Cellular Neuroscience, 0, 17, .	3.7	1
524	Novel Compounds in the Treatment of Schizophrenia—A Selective Review. Brain Sciences, 2023, 13, 1193.	2.3	2
526	Oxidative stress and neurodegenerative diseases: Exploring natural antioxidants for therapeutic potential. IP International Journal of Comprehensive and Advanced Pharmacology, 2023, 8, 149-158.	0.3	0